Funding for this research was provided by:
Medical Research Council (MR/M003108/1)
Received: 4 November 2018
Accepted: 4 February 2019
First Online: 20 February 2019
Ethics approval and consent to participate
: The study was approved by the Queen Square Research Ethics Committee and all participants provided written informed consent.
: Not applicable.
: K. Blennow has served as a consultant or at advisory boards for Alzheon, Eli Lilly, Fujirebio Europe, IBL International, Novartis, and Roche Diagnostics and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. J. Schott has received research funding from AVID Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly), has consulted for Roche Pharmaceuticals and Eli Lilly, and serves on a Data Safety Monitoring Committee for Axon Neuroscience SE. H. Zetterberg is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg, and has served on scientific advisory boards of Roche Diagnostics, Eli Lilly, Samumed, CogRx, and Wave. N. Fox reports fees (paid to University College London) for consultancy from Janssen, Eli Lilly, Novartis, Sanofi, Roche, and GlaxoSmithKline and for serving on a data monitoring committee for Biogen. The other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.